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1682-606X/Copyright ª 2014, TaiwanSummary Gastrointestinal stromal tumors (GISTs) are the most common malignant mesen-
chymal neoplasms of the digestive tract. Although surgery yields a high cure rate for low-
risk GISTs, it can seldom cure high-risk tumors because the postoperative recurrence rate of
GISTs is typically high; however, the prognosis substantially improves after imatinib mesylate
therapy. A case is reported of recurrent GIST presenting as an incarcerated inguinal hernia to
emphasize the importance of adjuvant therapy, particularly when treating advanced GISTs.
Malignancy in the hernia sac should be considered if a patient has a history of intraabdominal
malignancy.
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Gastrointestinal stromal tumours (GISTs) are common
mesenchymal tumors arising in the wall of the gastroin-
testinal tract. Complete surgical resection is the primary
treatment. However, postsurgical tumor recurrence is
common, and adjuvant imatinib mesylate (IM) therapy is
prescribed for patients with an increased risk of recur-
rence.1 A patient who underwent surgical resection for a
GIST over the distal jejunum is reported. Nevertheless, he
was lost to regular follow-up after the wound stitches were
removed and he missed IM therapy. Subsequently, heElsevier Taiwan LLC. All rights reserved.
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region and the pathological report confirmed a metastatic
GIST.
2. Case report
The patient was an 82-year-old man who presented with a
nonreducible, painful, and tender mass lesion over the right
groin region. The patient, who was a retired porter with a
history of chronic bronchitis, approached our general sur-
gery outpatient clinic. Physical examination revealed a
fixed, hard, painful, tender, and nonreducible mass over
the right inguinal region. An inguinal hernia with incarcer-
ation was first suspected according to the physical exami-
nation. The patient’s medical history showed that he had
sustained a malignant GIST over the distal jejunum with
rupture status following an operation within 2 years prior to
this examination. However, we neglected to provide the
patient with follow-up treatment at our outpatient clinic
after the stitches had been removed. As the patient had a
history of an intra-abdominal malignant tumor, a contrast-
enhanced abdominal and pelvic computed tomography (CT)
scan was immediately arranged because tumor recurrence
was suspected, which may have herniated into the inguinal
region. The CT results showed a well-defined heteroge-
neous mass lesion over the right inguinal region (Fig. 1). In
addition, multiple intra-abdominal peritoneal carcinoma-
tosis with lymphadenopathy in the pelvic region was noted.
The patient presented with symptoms of persistent pain
and signs of incarceration, and was at a high risk of tumor
recurrence with herniation to the right inguinal region. The
surgery indications were explained to the patient and ar-
ranged for surgical intervention after receiving his consent.
When exploring the right groin, a sliding hernia was iden-
tified through the right internal ring with a stalk leading
from the peritoneum (Fig. 2A). After opening the hernial
sac, a well-capsuled, hard, ovoid mass with a denseFigure 1 Ovoid heterogeneous mass over right inguinal re-
gion (arrow).adhesion to the hernial sac was identified (Fig. 2B and C).
After dissecting the sac from the cord, high ligation was
performed by removing the tumor with the sac simulta-
neously. The weak posterior wall was repaired using Bas-
sini’s technique. After opening the resected specimen, a 4-
cm grayish-white tumor exhibiting no signs of necrosis or
hemorrhage was observed. The pathology revealed a GIST
composed of cigar-shaped interlacing cell fascicles and a
high mitotic index (>5/50 HPF). Immunohistochemistry
showed CD117 (þ) (Fig. 3). Finally, the pathology report
confirmed a recurrent metastatic GIST with herniation to
the right inguinal region. Following surgery, imatinib
(400 mg/d) was prescribed for the patient. After 3 months
of treatment, contrast-enhanced abdominal and pelvic CT
scans were ordered for the patient, and noted shrinkage of
the lymphadenopathy over the pelvic region. No tumor
recurrence or other complications were noted after a 2-
year follow-up.3. Discussion
GISTs are rare visceral sarcomas arising in the gastrointes-
tinal tract wall, the muscularis mucosa, and muscularis
propria, anywhere from the esophagus to the rectum. Its
most common anatomic sites of origin are the stomach
(60e70%), small intestine (20e30%), colon and rectum (5%),
abdominal cavity (i.e., the peritoneum and omentum, 5%),
esophagus (<5%), and retroperitoneal space (<3%).2,3
Surgery is the standard treatment for primary GISTs;
however, surgical resection is seldom curative, particularly
for large GISTs. Furthermore, >50% of the patients with
GIST present with locally advanced, recurrent, or meta-
static disease, making treatment difficult. The 5-year sur-
vival rate ranges from 50% to 65% following complete
resection of a localized primary GIST, although this is
reduced to w35% for patients with advanced disease who
undergo complete surgical resection.4 The most commonly
applied scheme for assessing the risk of recurrence is the
consensus approach, which is based on the primary tumor
diameter and mitotic count.5 However, patients whose
tumor has ruptured into the abdominal cavity, either before
or during surgery, are at a high risk of tumor recurrence.
This patient suffered from a GIST with a rupture, implying
that the risk of tumor seeding was high. Furthermore, he
had not received a regular follow-up at our outpatient
clinic (including an abdominal CT scan and postoperative
medication). Hence, we could not detect the recurrence
earlier and take preventative measures until he presented
at our clinic with symptoms mimicking an incarcerated
inguinal hernia. Finally, an intraabdominal peritoneal
carcinomatosis of the GIST with tumor herniation was
identified in the right inguinal region.
Curative medication (IM) is available as a follow-up
treatment of GISTs. Approximately 80% of GISTs have a
mutated KIT gene, and 5% have a mutated alfa-type
platelet-derived growth factor gene.6 Imatinib is a
potent, specific inhibitor of KIT exhibiting significant ac-
tivity and tolerability in the treatment of malignant unre-
sectable or metastatic GISTs. Previous research showed
that imatinib either induced tumor shrinkage (50%) or
stabilized the disease in a majority of patients.5 Most
Figure 2 (A) Sliding hernia over internal ring with a stalk leading from peritoneum (arrow). (B, C) Transected hernia sac with a
stalk. A grayish-white tumor without any necrosis or hemorrhage was noted after opening the sac (arrow).
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imatinib or achieve durable tumor growth stabilization with
continual therapy by using a daily dose of 400e600 mg.5 Our
negligence resulted in the loss of the patient to regular
follow-up (abdominal CT), including the nonprescription of
imatinib following the first surgery. However, the patient
responded well to imatinib treatment following the second
surgery, exhibiting shrinkage of an enlarged lymph node in
the pelvis and no tumor recurrence. Therefore, we
recommend that other physicians prescribe imatinib and
conduct persistent follow-up treatments for the surgical
intervention of GISTs, particularly for patients at a high risk
of tumor recurrence, including those with ruptured or large
tumors, or with a high mitotic index.
Incarceration occurs in approximately 5% of hernias.
Emergency surgery is typically necessary because differ-
entiating between viable and nonviable contents of the
hernia sac is difficult. Previous studies have reported ma-
lignancies within the hernial sac when the hernia contains
small pieces of the bowel and omentum. The first case of a
tumor within a hernia sac was reported in 1749.7 The mostFigure 3 Stromal tumor present showing a spindled pattern
with myxoid change and composed of cells arranged in distinct
fascicles. The tumor is highly cellular with significant atypia
(hematoxylin and eosin stain,  400).frequently reported tumors are of primary or metastatic
colon cancer.8 Any patient with a history of intraabdominal
malignancy presenting with a new hernia should be exam-
ined for tumor recurrence. A history of intraabdominal
neoplasms and systemic symptoms such as unexplained
weight loss, anemia, altered bowel habit, or rectal bleeding
indicates the possibility of a malignancy or colonic
neoplasm.9 If an abnormal nodular sac is noted during
surgery, it should be examined to exclude a malignancy.
The patient approached our outpatient clinic complaining
of pain and tenderness. He presented with an irreducible
mass lesion over the right inguinal region that mimicked the
symptoms and signs of an incarcerated hernia. Had we been
unaware of his previous case of the GIST, we could have
misdiagnosed the patient’s illness.
4. Conclusion
GISTs are common mesenchymal tumors arising in the wall
of the gastrointestinal tract, typically reoccurring following
surgery. The primary prognostic factors are mitotic activity
and tumor size; furthermore, tumor rupture is a risk factor
for postoperative recurrence. Thus, adjuvant IM therapy
should be prescribed to patients at high risk of recurrence.
In addition, the simultaneous occurrence of an inguinal
hernia and cancer is rare, and easily overlooked. Relevant
literature shows that the most common cause is either
primary or metastatic colorectal cancer, other intra-
abdominal malignancies have seldom been reported. In
conclusion, patients with primary or metastatic GISTs can
present with symptoms similar to those of incarcerated
hernias. When diagnosing inguinal hernias, particularly
among patients that exhibit a history of intraabdominal
malignancies, physicians should consider whether malig-
nancy is present. Contrast-enhanced abdominal and pelvic
CT scans are effective tools for differentially diagnosing the
case patient.
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